Form 4: TELA Bio Director Federica O'Brien Receives Equity Compensation Awards

TELA Bio, Inc. Director Federica F. O'Brien was granted 7,950 restricted stock units and 11,700 stock options as part of her compensation, aligning her interests with shareholders.

Summary

• Federica F. O'Brien, a Director of TELA Bio, Inc. (TELA), reported changes in her beneficial ownership of company securities.
• On May 28, 2025, Ms. O'Brien acquired 7,950 shares of Common Stock in the form of Restricted Stock Units (RSUs) at a price of $0 per share.
• These RSUs will vest on the earlier of May 28, 2026, the next annual meeting of stockholders, or a Change in Control, contingent on her continued service.
• Additionally, on May 28, 2025, she acquired 11,700 Stock Options (Right to Buy) with an exercise price of $1.39 per share.
• The stock options also vest on the earlier of May 28, 2026, the next annual meeting of stockholders, or a Change in Control, subject to her continued service.
• The stock options have an expiration date of May 28, 2035.
• Following these transactions, Ms. O'Brien beneficially owns 18,470 shares of Common Stock directly and 11,700 derivative securities (stock options) directly.

Sentiment

Score: 6

Explanation: The sentiment is mildly positive as it indicates standard corporate governance practices for director compensation, aligning insider interests with shareholders. It is not a significant market-moving event but reflects ongoing operational norms.

Positives

• The grant of restricted stock units and stock options to a director aligns their financial interests with those of the company's shareholders, encouraging long-term value creation.
• Equity compensation is a standard practice for retaining and incentivizing key personnel and board members.

Risks

• The value of the granted restricted stock units and stock options is subject to the future performance of TELA Bio's common stock.
• Vesting of both the RSUs and stock options is contingent upon Ms. O'Brien's continued service to the company through the specified vesting dates.

Future Outlook

The vesting schedule for the equity awards indicates a future commitment from the director to continued service, aligning with the company's long-term strategic goals.

Industry Context

This filing reflects a routine equity compensation grant to a director, a common practice across publicly traded companies in various industries, including the biotechnology and medical device sectors where TELA Bio operates. Such grants are designed to attract, retain, and incentivize board members by linking their compensation to the company's stock performance.

Comparison to Industry Standards

• The grant of restricted stock units and stock options as part of director compensation is a standard practice within the U.S. public company landscape, consistent with corporate governance best practices aimed at aligning director and shareholder interests.
• While specific grant sizes vary by company size, industry, and individual director responsibilities, the structure of these equity awards (RSUs and options with service-based vesting) is typical for non-employee directors in companies of similar market capitalization to TELA Bio.

Related Party Transactions

• The acquisition of restricted stock units and stock options by Federica F. O'Brien, a director of TELA Bio, Inc., constitutes a related party transaction as it involves compensation from the company to an insider.

Stakeholder Impact

• Shareholders: The equity grants align the director's financial interests with those of the shareholders, potentially encouraging decisions that enhance long-term shareholder value.
• Employees: No direct impact on general employees is indicated by this specific filing.

Next Steps

• Continued service of Federica F. O'Brien to TELA Bio, Inc. for the equity awards to vest.
• Future SEC Form 4 filings will report any subsequent changes in beneficial ownership by Ms. O'Brien.

Key Dates

Keywords

TELA Bio, TELA, SEC Form 4, Insider Transaction, Equity Compensation, Restricted Stock Units, Stock Options, Director Compensation, Beneficial Ownership, Corporate Governance